Bio-Techne Earnings Call Balances Headwinds With Margin Gains

Bio-Techne ((TECH)) has held its Q2 earnings call. Read on for the main highlights of the call.

Bio-Techne’s latest earnings call painted a cautiously optimistic picture, with management emphasizing solid execution and strategic progress despite visible near-term headwinds. Adjusted EPS rose double digits and operating margins expanded, supported by cost discipline and robust cash generation. At the same time, flat top-line growth, gross margin pressure, and sharp order timing disruptions from a handful of large cell therapy customers underscored the challenges facing the business in the current funding and demand environment. Overall, the tone suggested confidence in the company’s medium‑term trajectory, even as management acknowledged a few choppy quarters ahead.

Adjusted EPS Growth Signals Resilience

Bio-Techne delivered adjusted EPS of $0.46, up 10% year-over-year, with foreign exchange contributing roughly $0.04 of the upside. GAAP EPS also improved modestly to $0.24 from $0.22 a year ago. This earnings growth came despite flat revenue, indicating that the company is leveraging productivity and cost controls to drive profitability in a tough macro and funding backdrop. For investors, the EPS expansion shows that Bio-Techne can still grow the bottom line even when the top line is temporarily constrained.

Margin Expansion Backed by Tight Expense Discipline

Adjusted operating margin climbed about 100 basis points to 31.1%, driven by productivity initiatives, cost management, and the divestiture of the Exosome Diagnostics business. Operating efficiency showed up clearly in the expense lines: adjusted SG&A fell to 29.6% of revenue, down 240 basis points, while R&D spending eased to 7.8% from 8.5%. The company is effectively reallocating resources while preserving innovation, giving it room to protect profitability and reinvest strategically even as certain markets remain soft.

Revenue Flat, but Underlying Growth Looks Better Ex-Cell Therapy

Total revenue for the quarter was $295.9 million, flat year-over-year both on a reported and organic basis. However, when excluding sizeable order-timing impacts from two major cell therapy customers, Bio-Techne estimates underlying organic growth was closer to 4%. Foreign exchange added about a 2% tailwind, while businesses held for sale contributed a roughly 2% headwind. The picture suggests a business that is still growing at a modest pace beneath the noise created by a concentrated set of cell therapy customers.

Proteomic Instruments and Innovation Stand Out

Despite what management described as a constrained capital spending environment, ProteinSimple instruments posted upper single-digit growth, a solid performance against macro headwinds. Product innovation was a key driver: Bio-Techne highlighted new ultra-sensitive Ella assays that improve sensitivity by two- to five-fold and growing enthusiasm for LEO, the company’s next-generation Simple Western platform. Recent fluorescence multiplexing enhancements are helping LEO gain traction with customers seeking higher-throughput, more informative protein analysis workflows.

Spatial Biology and Comet Booking Strength

Spatial biology remains a strategic growth pillar, and the automated Comet platform delivered another strong quarter. Bookings for Comet grew nearly 40%, marking the second consecutive quarter of strong intake. On the assay side, RNAscope diagnostic adoption increased more than 20% for both the quarter and the first half, reflecting rising clinical and translational use. RNAscope research sales grew at a low single-digit pace, slower but still positive, indicating that while research budgets are pressured, adoption continues to broaden.

Diagnostics Growth Supported by Molecular Kit Adoption

Bio-Techne’s Diagnostics segment posted high single-digit growth, driven by clinical controls and molecular diagnostic kits. The company highlighted growing use of its ESL One exosome-based mutation kit and the Amplidex Carrier Screening Plus offering, underscoring how targeted molecular tools are gaining traction with clinical laboratories. These products provide more resilient demand streams and help balance softness in more cyclical research and capital spending categories.

Geographic Strength in China and Broader APAC

Geographically, China delivered mid-single-digit growth, representing the third consecutive quarter of expansion and suggesting stabilization after an extended period of uncertainty in that market. The rest of Asia-Pacific was even stronger, with nearly 20% growth. Management noted that, excluding the cell therapy order-timing headwinds, the Americas would have shown low single-digit growth as well. The regional performance highlights Bio-Techne’s diversified footprint and the importance of APAC as a growth engine.

Wilson Wolf and Organoid Platforms Gain Momentum

Bio-Techne’s strategic stake in Wilson Wolf is paying off, with the cell and gene therapy tools company delivering 20% organic revenue growth in the quarter and upper-teens growth on a trailing twelve-month basis. Bio-Techne, which owns 20% today, reiterated its expectation to complete the full acquisition by the end of calendar 2027. Separately, the company’s organoid-related portfolio has grown into a roughly $50 million run-rate business. A key launch this quarter was Culturex Synthetic Hydrogel, designed to support non-animal organoid workflows—positioning Bio-Techne to benefit from the shift toward more physiologically relevant and ethically attractive model systems.

Robust Cash Generation and Healthy Balance Sheet

The company generated $82.4 million in operating cash flow, with modest net capex of $5.9 million, underscoring strong cash conversion despite variable working-capital patterns. Bio-Techne ended the quarter with $172.9 million in cash and $260 million in bank debt, which was reduced by $40 million sequentially. Leverage sits well below 1x EBITDA, providing flexibility for future M&A and strategic investments. The company also returned $12.5 million to shareholders via dividends, signaling confidence in its financial position.

Flat Top Line and Organic Growth Reflect Market Softness

While profitability metrics moved in the right direction, the top line told a more muted story. Total revenue of $295.9 million was flat year-over-year, as was organic growth. Management pointed to order-timing disruptions and weak demand in pockets of biotech and academia as the main culprits. For investors, the stagnating revenue base is a reminder that Bio-Techne is not fully insulated from broader funding and capital spending cycles in life sciences.

Cell Therapy Order Timing Creates Significant Near-Term Drag

The largest single headwind came from two major cell therapy customers that recently received FDA Fast Track designations. The regulatory progress triggered a pause and reset in ordering patterns, leading those customers to meaningfully reduce near-term purchases. As a result, Bio-Techne’s cell therapy revenue fell more than 30% year-over-year, and GMP reagent revenue dropped roughly 50%. Management estimates that this dynamic alone will shave about 300 basis points off Q3 growth, with the impact moderating in subsequent quarters as ordering normalizes.

Gross Margin Pressure from Unfavorable Mix

Adjusted gross margin declined to 68.5% from 70.5% a year ago, a roughly 200-basis-point contraction. The pressure stemmed from an unfavorable product and customer mix, including a higher proportion of reagents relative to higher-margin instruments and increased contributions from lower-margin OEM orders. Within the Protein Sciences segment, operating margin slipped by about 190 basis points to 39.3%. While not structural, the mix shift highlights the sensitivity of Bio-Techne’s margins to end-market and customer dynamics.

Divestiture Weighs on Diagnostics & Spatial Biology Sales

Diagnostics & Spatial Biology reported revenue of $81.2 million, down 4% year-over-year. The Exosome Diagnostics divestiture was the primary driver, shaving about 8% from reported growth. Spatial biology, meanwhile, was roughly flat against a difficult comparison period. Stripping out the divestiture, underlying activity in diagnostics and spatial appears healthier than the headline revenue decline suggests, but investors will continue to watch the pace of growth in these strategic areas.

Biotech and U.S. Academia Feel Funding Strain

End-market trends remained mixed, with emerging biotech revenue down mid-single digits and U.S. academia showing a modest decline, leading to a low single-digit downturn for academia overall. Management linked the softness to ongoing funding and budget pressures heading into 2025, even as some recent funding indicators have turned more encouraging. This cautious spending posture from key research customers is an important backdrop for Bio-Techne’s near-term growth prospects.

Additional Q3 Headwind from OEM Order Timing

Beyond cell therapy, the quarter also benefited from an OEM commercial supply order that typically would have been recognized in Q3. Pulling that revenue into Q2 will create about a 100-basis-point headwind to Q3 growth. The shift does not reflect lost business but adds another layer of volatility to near-term reported numbers, reinforcing the “lumpy” nature of some of Bio-Techne’s revenue streams.

Cash Flow Timing, Interest Costs, and Taxes Add Noise

First-half operating cash flow was down compared with the prior year, largely due to timing of incentive bonus payouts and tax payments rather than any deterioration in the core business. Net interest expense increased by about $0.5 million year-over-year as certain interest rate hedges expired, while the adjusted effective tax rate rose roughly 80 basis points to 22.3%. These factors modestly pressured net income but are largely financial and timing considerations rather than operational red flags.

Customer Concentration Highlights Lumpy Demand Risk

The quarter underscored Bio-Techne’s exposure to a small number of large cell therapy customers, whose ordering decisions can swing results. These customers historically represented a significant portion of GMP reagent volumes, and their temporary pullback drove the steep decline in that category. Management framed this as a timing and order-pattern issue rather than a loss of share, but the episode highlights concentration risk that equity investors will need to factor into their assessment of earnings volatility.

Guidance Points to Modest Near-Term Growth and Margin Upside

Looking ahead, Bio-Techne guided for Q3 organic growth to be roughly in line with Q2’s flat performance, but with an explicit ~300 basis-point drag from the two large cell therapy customers and an additional ~100-basis-point headwind from OEM order timing. Management expects the cell-therapy drag to ease to about 100–200 basis points in Q4 and to be fully lapped in fiscal 2027. Excluding these timing and customer-specific effects, the company believes underlying growth should run in the mid-single digits, building from roughly 1% underlying growth in Q1 and 3% in Q2. Achieving the full-year outlook of low single-digit growth will require mid-single-digit expansion in Q4. On profitability, Bio-Techne remains on track to expand adjusted operating margin by about 100 basis points for the full year, driven half by improving gross-margin mix and half by higher revenue in the back half. Management also reiterated confidence that improving biotech funding trends, sustained China and APAC strength, and a low-leverage balance sheet will support both organic investments and future M&A.

In sum, Bio-Techne’s earnings call mixed solid margin and cash performance with a flattish revenue profile and temporary but significant headwinds from large cell therapy customers. Management’s message was that the underlying demand picture is improving beneath the surface noise, with instruments, diagnostics, spatial biology, APAC, and strategic platforms like Wilson Wolf and organoids all contributing to a constructive medium-term story. For investors, the coming quarters may remain uneven, but the company’s cost discipline, innovation pipeline, and balance-sheet strength suggest it is positioned to emerge stronger as funding and order patterns normalize.